Metastatic renal cell cancer--is the outlook really improving?
作者信息
Waxman J, Thomas H
机构信息
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
出版信息
Postgrad Med J. 1990 Jun;66(776):435-40. doi: 10.1136/pgmj.66.776.435.
Abstract
摘要
相似文献
1
Metastatic renal cell cancer--is the outlook really improving?转移性肾细胞癌——前景真的在改善吗？
Postgrad Med J. 1990 Jun;66(776):435-40. doi: 10.1136/pgmj.66.776.435.
2
Metastatic renal cell carcinoma: systemic treatment.转移性肾细胞癌：全身治疗
Acta Urol Belg. 1996 May;64(2):3-8.
3
High-dose interleukin-2 in metastatic renal cell carcinoma.高剂量白细胞介素-2治疗转移性肾细胞癌
J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9. doi: 10.1200/JCO.2005.02.1709.
4
Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer.转移性肾细胞癌的全身化疗和化疗免疫疗法
World J Urol. 2001 Apr;19(2):111-9. doi: 10.1007/s003450000191.
5
High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.高剂量白细胞介素-2治疗转移性肾细胞癌和转移性黑色素瘤：仍然是标准疗法。
Oncology (Williston Park). 2011 Apr 30;25(5):427-8.
6
[Interferon-based cytokine therapy for advanced renal cell carcinoma].[基于干扰素的细胞因子疗法治疗晚期肾细胞癌]
Hinyokika Kiyo. 2005 Aug;51(8):499-502.
7
Systemic therapy in metastatic renal cell carcinoma.
Scand J Surg. 2004;93(2):156-61. doi: 10.1177/145749690409300212.
8
[Management of adverse events with interferon and interleukin-2].[干扰素和白细胞介素-2不良事件的管理]
Nihon Rinsho. 2015 Feb;73 Suppl 2:322-8.
9
Improving the therapeutic index of IL-2.提高白细胞介素-2的治疗指数。
Clin Adv Hematol Oncol. 2010 Dec;8(12):862-4.
10
The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
Nat Clin Pract Oncol. 2008 Dec;5(12):698-9. doi: 10.1038/ncponc1256. Epub 2008 Oct 14.
本文引用的文献
1
Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: a Southwest Oncology Group Study.他莫昔芬治疗转移性肾细胞癌的研究及某些预后因素的影响：西南肿瘤学组研究
Cancer Treat Rep. 1981 May-Jun;65(5-6):447-51.
2
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide.肾细胞癌中的雌激素、孕激素和雄激素结合位点。在氟他胺II期试验中获得的观察结果。
Cancer. 1984 Aug 1;54(3):477-81. doi: 10.1002/1097-0142(19840801)54:3<477::aid-cncr2820540316>3.0.co;2-k.
3
Renal cell carcinoma: antitumor effects of leukocyte interferon.
Cancer Res. 1983 Feb;43(2):940-7.
4
Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy.肾细胞癌中的激素受体及其与内分泌治疗临床反应的相关性
J Urol. 1984 Aug;132(2):240-5. doi: 10.1016/s0022-5347(17)49577-2.
5
6
High-dose methotrexate with leucovorin rescue, vinblastine, and bleomycin with or without tamoxifen in metastatic renal cell carcinoma.
Cancer Treat Rep. 1984 Apr;68(4):587-90.
7
Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer.醋酸甲羟孕酮（普维拉）治疗转移性肾癌。
Br J Cancer. 1971 Jun;25(2):250-65. doi: 10.1038/bjc.1971.31.
8
Increased dihydrotestosterone receptor levels in high-stage renal adenocarcinoma.晚期肾腺癌中双氢睾酮受体水平升高。
Cancer. 1985 Jul 1;56(1):134-7. doi: 10.1002/1097-0142(19850701)56:1<134::aid-cncr2820560121>3.0.co;2-j.
9
Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine.CCNU与长春花碱联合化疗晚期肾细胞癌
Cancer Chemother Pharmacol. 1985;14(3):277-8. doi: 10.1007/BF00258134.
10
Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Cancer Treat Rep. 1985 Mar;69(3):263-7.
Zotero 插件